

## Teva announces US launch of Vigabatrin

08 February 2019 | News | By Kalyani Sharma

**SABRIL® tablets had annual sales of \$180 million in the U.S**



Teva Pharmaceutical Industries has announced the launch of a generic version of Sabril®1 (vigabatrin) tablets, 500 mg in the US, the first generic version of Sabril® (vigabatrin) tablets to enter the US market.

Vigabatrin oral tablets are indicated as adjunctive therapy for adults and children (10 years of age or older) with refractory complex partial seizures (CPS) who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss. Vigabatrin tablets are not indicated as a first line treatment for CPS.

Brendan O'Grady, EVP and Head of North America Commercial at Teva said, "This launch represents a notable addition to our generics portfolio and underscores our commitment to ensuring that patients with complex, chronic conditions have more treatment options."

SABRIL® tablets had annual sales of \$180 million in the U.S., according to IQVIA data as of November 2018.

Vigabatrin tablets are indicated as adjunctive therapy for adults and pediatric patients 10 years of age and older with refractory complex partial seizures who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss.